Literature DB >> 28657237

Response: Regulating Hypothalamus Gene Expression in Food Intake: Dietary Composition or Calorie Density? (Diabetes Metab J 2017;41:121-7).

Mi Jang1, So Young Park1, Yong Woon Kim1, Seung Pil Jung1, Jong Yeon Kim2.   

Abstract

Entities:  

Year:  2017        PMID: 28657237      PMCID: PMC5489504          DOI: 10.4093/dmj.2017.41.3.225

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


× No keyword cloud information.
We appreciate Dr. Koo's interest and comments on our article entitled “Regulating hypothalamus gene expression in food intake: dietary composition or calorie density?” which was published in Diabetes and Metabolism Journal [1]. The regulation of appetite and food or energy intake is fundamental to body weight control. The epidemiological evidence that a high intake of dietary fat has long been thought to be implicated in the development of obesity with a positive association with a high-fat (HF), high-energy, dense diet but is not yet definitive [2]. Previously, some studies showed dietary fat has relatively weak effect on satiating effect compared to isoenergetic amounts of carbohydrate (CHO) in most [3], although not all [4]. However, it is not only the macronutrient content of the diet but also the energy content that may be affecting food intake. The energy intake, and hence the satiating effects of fat and CHO, were very similar in HF and high-CHO diets so long as the energy density was the same [5]. These results support our results that calorie density of diet may be more critical factor than fat composition in food intake. However, Dr. Koo's opinions are that polyunsaturated fatty acid (PUFA) increases proopiomelanocortin (POMC) expression [67], and saturated fatty acid (SFA) feeding did not alter POMC expression level [89]. On the other hand, we reported that purified high SFA or n-3 PUFA significantly increased POMC mRNA expression 2 hours after intragastric administration compared with baseline. The increase in the level of POMC expression was highest in CHO-rich diet group followed by SFA-rich diet group, and the lowest was in n-3 PUFA-rich diet group. The possible reason for the different results might be the different experimental designs and methods between ours and those of other studies [6789]. We analyzed gene expressions 2 hours after intragastric administration of purified fatty acids dissolved in dimethyl sulfoxide, and after CHO-rich or fat-rich diet feeding ad libitum for just 15 hours. On the other hand other studies analyzed gene expressions after long-term diet feeding. While our experiment focused on the acute effects of purified fatty acids and dietary composition on hypothalamic gene expressions, other studies focused on the chronic effects of dietary composition. In a recent report, there was no evidence of differential effects of dietary fat composition on changes in postingestive satiety and energy intake in lean and healthy men [10]. This result is also different from Dr. Koo's opinion. In addition, Dr. Koo noticed that glucagon-like peptide-1 (GLP-1) reduces food intake [1112]. GLP-1 response increased with fat-rich meal compared with isocaloric CHO-rich meals in human [13], and dietary fat composition also affected GLP-1 response: unsaturated fatty acids increased GLP-1 more than SFA [14]. Considering that GLP-1 reduces food intake by directly stimulating POMC/cocaine and amphetamine regulated transcript (CART) neurons [1112], there is a discrepancy with our findings and previous studies [1112] in that CHO-rich meal and SFA increased POMC expression level more than PUFA. We agree with Dr. Koo's opinion that GLP-1 reduces food intake by stimulating POMC/CART neurons. Interestingly, GLP-1 response at early phase (30 minutes) after eating was higher after CHO-rich meal compared with fat-rich meal, and SFA meal caused more GLP-1 response than PUFA meal, but opposite results were observed at late phase (6 hours after eating) (Fig. 2A of [15]). The early phase response of GLP-1AUC(0–2 hr) was 27% and 23% higher after CHO-rich meal compared with monounsaturated fatty acid (MUFA) and n-6 PUFA meals, respectively (Fig. 2A of [15]). This result suggest that POMC expression by GLP-1 stimulation could be higher in CHO-rich meal group than in fat-rich meal, which is in accordance with our results. There are more evidence that fatty acid composition differentially affected GLP-1 response, but different GLP-1 responses among different diet composition groups was not associated with changes in subjective appetite ratings or changes in energy intake when alterations were made from an acute HF meal to fatty acid composition [16], and GLP-1 response in SFA-rich diet group tended to be somewhat higher than in PUFA-rich diet group at 150 minutes after eating (Fig. 1 of [16]). These results could be in agreement with ours although GLP-1 response was very variable depending on the time period after eating [1516]. Lastly, Dr. Koo noticed that plasma glucose, free fatty acid, lipid, leptin, and ghrelin levels are very important factors in satiety regulation. The food intake is regulated by physiological signals among the gastrointestinal tract, adipose tissue, and the hypothalamus. It is influenced by behavioral, neuronal, autonomic, nutritional, and endocrine mechanisms [17]. I expect that further study will be required to understand these processes further.
  17 in total

1.  Covert manipulation of the dietary fat to carbohydrate ratio of isoenergetically dense diets: effect on food intake in feeding men ad libitum.

Authors:  R J Stubbs; C G Harbron; A M Prentice
Journal:  Int J Obes Relat Metab Disord       Date:  1996-07

Review 2.  Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain.

Authors:  César Luiz Boguszewski; Gilberto Paz-Filho; Licio A Velloso
Journal:  Endokrynol Pol       Date:  2010 Mar-Apr       Impact factor: 1.582

Review 3.  Dietary fat and obesity: a review of animal, clinical and epidemiological studies.

Authors:  George A Bray; Sahasporn Paeratakul; Barry M Popkin
Journal:  Physiol Behav       Date:  2004-12-30

4.  Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression.

Authors:  X-F Huang; X Xin; P McLennan; L Storlien
Journal:  Diabetes Obes Metab       Date:  2004-01       Impact factor: 6.577

Review 5.  Fats and food intake.

Authors:  Stephen French; Tristan Robinson
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2003-11       Impact factor: 4.294

6.  No evidence of differential effects of SFA, MUFA or PUFA on post-ingestive satiety and energy intake: a randomised trial of fatty acid saturation.

Authors:  Caroline M Strik; Fiona E Lithander; Anne-Thea McGill; Alastair K MacGibbon; Brian H McArdle; Sally D Poppitt
Journal:  Nutr J       Date:  2010-05-24       Impact factor: 3.271

7.  Hunger and satiety responses to high-fat meals of varying fatty acid composition in women with obesity.

Authors:  Jada L Stevenson; Hui C Clevenger; Jamie A Cooper
Journal:  Obesity (Silver Spring)       Date:  2015-09-01       Impact factor: 5.002

8.  A MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects.

Authors:  Juan A Paniagua; Angel Gallego de la Sacristana; Esther Sánchez; Inmaculada Romero; Antonio Vidal-Puig; Francisco J Berral; Antonio Escribano; Maria José Moyano; Pablo Peréz-Martinez; José López-Miranda; Francisco Pérez-Jiménez
Journal:  J Am Coll Nutr       Date:  2007-10       Impact factor: 3.169

9.  Satiety after preloads with different amounts of fat and carbohydrate: implications for obesity.

Authors:  B J Rolls; S Kim-Harris; M W Fischman; R W Foltin; T H Moran; S A Stoner
Journal:  Am J Clin Nutr       Date:  1994-10       Impact factor: 7.045

Review 10.  Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.

Authors:  Bruno Geloneze; José Carlos de Lima-Júnior; Lício A Velloso
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.